Literature DB >> 18208785

Incorporating new therapies in the treatment of paediatric solid tumours.

S Gallego Melcón.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18208785     DOI： 10.1007/s12094-008-0145-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  7 in total

1.  A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.

Authors:  Diana Stempak; Janet Gammon; Jacqueline Halton; Albert Moghrabi; Gideon Koren; Sylvain Baruchel
Journal:  J Pediatr Hematol Oncol       Date:  2006-11       Impact factor: 1.289

2.  Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry.

Authors:  Stefano Ceschel; Veronica Casotto; Maria Grazia Valsecchi; Paolo Tamaro; Momcilo Jankovic; Guia Hanau; Franca Fossati; Marta Pillon; Roberto Rondelli; Alessandro Sandri; Daniela Silvestri; Riccardo Haupt; Marina Cuttini
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

3.  Tied up in red tape, European trials shut down.

Authors:  Brandon Keim
Journal:  Nat Med       Date:  2007-02       Impact factor: 53.440

Review 4.  Metronomic dosing of chemotherapy: applications in pediatric oncology.

Authors:  Diana Stempak; Dugald Seely; Sylvain Baruchel
Journal:  Cancer Invest       Date:  2006 Jun-Jul       Impact factor: 2.176

5.  Childhood cancer survival trends in Europe: a EUROCARE Working Group study.

Authors:  Gemma Gatta; Riccardo Capocaccia; Charles Stiller; Peter Kaatsch; Franco Berrino; Monica Terenziani
Journal:  J Clin Oncol       Date:  2005-06-01       Impact factor: 44.544

6.  Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group.

Authors:  A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

7.  Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.

Authors:  M Benesch; M Windelberg; W Sauseng; V Witt; G Fleischhack; H Lackner; H Gadner; U Bode; C Urban
Journal:  Ann Oncol       Date:  2007-12-03       Impact factor: 32.976
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.